

# Joerg Hasford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7030168/publications.pdf>

Version: 2024-02-01

60  
papers

3,875  
citations

304743

22  
h-index

144013

57  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. <i>Diabetologia</i> , 2021, 64, 1079-1092.	6.3	31
2	Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2021, , 119-143.	0.2	0
3	Implementation of a renal pharmacist consultant service "Information sharing in paper versus digital form. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 838-845.	1.5	3
4	Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards. <i>Journal of Medical Ethics</i> , 2021, 47, e82-e82.	1.8	5
5	Impact of the COVID-19 pandemic on clinical trials with drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1373-1375.	2.4	5
6	Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1683-1693.	1.9	7
7	Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines. <i>Journal of Infectious Diseases</i> , 2020, 222, 1571-1572.	4.0	2
8	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	7.2	55
9	Redundant trials can be prevented, if the EU clinical trial regulation is applied duly. <i>BMC Medical Ethics</i> , 2020, 21, 107.	2.4	18
10	Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study. <i>European Journal of Haematology</i> , 2019, 103, 362-369.	2.2	3
11	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	4.1	17
12	Screening for asymptomatic $\hat{t}^2$ -cell autoimmunity in young children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 288-290.	5.6	8
13	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	3.5	18
14	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. <i>Leukemia</i> , 2018, 32, 1222-1228.	7.2	22
15	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	2.5	14
16	Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. <i>Cancer</i> , 2017, 123, 2467-2471.	4.1	18
17	Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1167-1176.	2.5	67
18	Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1441-1447.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2016, , 111-128.	0.2	0
20	Tiotropium Respimat <sup>®</sup> vs. HandiHaler <sup>®</sup> : real-life usage and TIOSPIR trial generalizability. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 379-388.	2.4	12
21	Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial. <i>BMC Pulmonary Medicine</i> , 2015, 15, 55.	2.0	6
22	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. <i>Blood</i> , 2015, 126, 42-49.	1.4	171
23	Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. <i>Annals of Hematology</i> , 2015, 94, 209-218.	1.8	22
24	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. <i>Annals of Hematology</i> , 2015, 94, 2015-2024.	1.8	67
25	A multi-state model approach for prediction in chronic myeloid leukaemia. <i>Annals of Hematology</i> , 2015, 94, 919-927.	1.8	6
26	Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study. <i>PLoS ONE</i> , 2015, 10, e0117628.	2.5	11
27	Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children. <i>PLoS ONE</i> , 2014, 9, e105110.	2.5	10
28	The impact of health care settings on survival time of patients with chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 2494-2496.	1.4	27
29	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. <i>Leukemia Research</i> , 2014, 38, 57-64.	0.8	68
30	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	1.6	271
31	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. <i>Annals of Hematology</i> , 2014, 93, 71-80.	1.8	60
32	Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. <i>Annals of Hematology</i> , 2014, 93, 1167-1176.	1.8	21
33	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1367-1381.	2.5	5
34	Etiology and Epidemiology of Chronic Myeloid Leukemia. , 2013, , 11-17.		3
35	The EUTOS CML score aims to support clinical decision-making. <i>Blood</i> , 2012, 119, 2966-2967.	1.4	12
36	Medical registries represent vital patient interests and should not be dismantled by stricter regulation. <i>Cancer Epidemiology</i> , 2012, 36, 575-578.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. <i>Blood</i> , 2011, 118, 686-692.	1.4	413
38	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon- $\beta$ in Newly Diagnosed Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1634-1642.	1.6	307
39	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. <i>Blood</i> , 2011, 118, 6760-6768.	1.4	254
40	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. <i>Blood</i> , 2010, 115, 1880-1885.	1.4	198
41	Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment "a review. <i>Cardiovascular Diabetology</i> , 2009, 8, 18.	6.8	67
42	Epidemiology of chronic myeloid leukaemia (CML). <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 295-302.	1.7	119
43	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. <i>Blood</i> , 2009, 114, 4272-4272.	1.4	11
44	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia " An Interim Analysis of the Randomized German CML Study IV. <i>Blood</i> , 2008, 112, 333-333.	1.4	10
45	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 4686-4692.	1.4	141
46	Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1055-1061.	1.9	61
47	Incidence, Comorbidity and Treatment Survey of Chronic Myeloid Leukemia in Germany.. <i>Blood</i> , 2007, 110, 2964-2964.	1.4	4
48	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. <i>Blood</i> , 2006, 108, 4781-4781.	1.4	0
49	The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. <i>Haematologica</i> , 2005, 90, 335-40.	3.5	12
50	A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 443-447.	1.9	23
51	Chronic myeloid leukemia and interferon- $\beta$ : a study of complete cytogenetic responders. <i>Blood</i> , 2001, 98, 3074-3081.	1.4	309
52	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with $\beta$ -interferon: comments. <i>British Journal of Haematology</i> , 2001, 114, 241-241.	2.5	7
53	First results from an intensified monitoring system to estimate drug related hospital admissions. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 196-200.	2.4	28
54	Assessing the Safety of Drugs in Pregnancy. <i>Drug Safety</i> , 2000, 22, 169-177.	3.2	28

#	ARTICLE	IF	CITATIONS
55	Regional reporting of adverse drug reactions: a new computer-based network. , 1999, 8, S47-S53.		0
56	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute, 1998, 90, 850-859.	6.3	728
57	Drug use assessment and risk evaluation in pregnancy—the PEGASUS-project. Pharmacoepidemiology and Drug Safety, 1997, 6, S37-S42.	1.9	13
58	Drug risk assessment: A case for large trials with lean protocols. Pharmacoepidemiology and Drug Safety, 1994, 3, 321-327.	1.9	14
59	24-Hour blood pressure measurement in antihypertensive drug trials: Data requirements and methods of analysis. Statistics in Medicine, 1992, 11, 2147-2158.	1.6	20
60	Design and Analysis of Clinical Trials of Compliance. , 0, , 23-40.		3